News
Stevin Prize for Immunologist Ton Schumacher
Immunologist Ton Schumacher of the Netherlands Cancer Institute, also Professor at Leiden University Medical Center (LUMC), is being awarded the Stevin Prize. With the Spinoza Prize, the winners of which are also being announced today, this is the highest academic prize in the Netherlands. The Stevin Prize is awarded to researchers whose research has major social impact.
Smart Chemistry Rids Anti-Cancer Drugs of Serious Side Effects
Researchers led by Leiden University Medical Centre (LUMC) have made an important discovery regarding the widely used anti-cancer drug doxorubicin.
News article 1
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur congue mollis risus, imperdiet mollis velit convallis eu. Cras dui lorem, scelerisque at felis quis, convallis sodales ante.
Four European Countries Contract Possible Corona Vaccine
AstraZeneca heeft afspraken gemaakt met de Inclusieve Vaccin Alliantie (IVA), bestaande uit Nederland, Italië, Frankrijk en Duitsland, over de levering van een toekomstig coronavaccin. AstraZeneca stelt de vaccins beschikbaar zonder winstoogmerk.
Globalstars: Call Singapore
Oproep aan Nederlandse organisaties om een gezamenlijk R&D-projectvoorstel in te dienen met één of meerdere partners in Singapore.
MIT COVID-19 Challenge; Sequel in The Netherlands
On Friday the 12th of June, a couple of international teams that joined the MIT COVID-19 Challenge at the beginning of April had the opportunity to pitch their solutions against COVID-19 to a group of Dutch stakeholders from the Life Sciences & Health community to explore possibilities to implement their solution in the Netherlands.
Sirius Medical Announces CE Mark for Pintuition: to Improve Breast Cancer Surgery
Sirius Medical, a MedTech startup, announced that it has received CE mark approval for Sirius Pintuition. With its debut product, Sirius provides an affordable and easy-to-use alternative to traditional surgical localisation systems that rely on anchor wires or radioactive seeds. Sirius aims to revolutionise the way tumors are localised during surgery.
Johnson & Johnson Announces Acceleration of its COVID-19 Vaccine Candidate
Johnson & Johnson announced that through its Janssen Pharmaceutical Companies (Janssen) it has accelerated the initiation of the Phase 1/2a first-in-human clinical trial of its investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant. Initially scheduled to begin in September, the trial is now expected to commence in the second half of July.
Annual Report 2019 of Regieorgaan SIA
Het jaar 2019 was een goed jaar voor het praktijkgerichte onderzoek en Regieorgaan SIA. Ze verkenden de toekomst van het praktijkgerichte onderzoek, reikten de eerste Deltapremies uit en ondertekenden met NWO het Kennis en Innovatieconvenant 2020-2023.
News article 2
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur congue mollis risus, imperdiet mollis velit convallis eu. Cras dui lorem, scelerisque at felis quis, convallis sodales ante.